Skip to main content
Funded Studies

Scott Shandler, PhD, MBA

CEO at Longevity Biotech, Inc.

Location: Philadelphia, PA United States

Dr. Scott Shandler is a CEO and principal investigator at Longevity Biotech and has been responsible for business development, fund raising and industry collaborations with other organizations. Previously, Dr. Shandler was a venture capitalist at BioAdvance, focused on investing in early-stage therapeutics companies. Earlier in his career, Dr. Shandler worked for Merck Research Labs, where he guided project portfolio prioritization efforts across the worldwide basic research neuroscience portfolio. Prior to Merck, he was a product manager for PolyMedix, an early-stage biotech company, and served as a subject matter expert in Accenture’s (ACN) Pharmaceutical and Medical Products group, advising leading pharmaceutical and biotechnology companies. Dr. Shandler received his PhD in biochemistry and molecular biophysics from the University of Pennsylvania and an MBA from The Wharton School. He also holds a BA in computer science from Brandeis University and a certificate of bioinformatics from Stanford University.

Associated Grants

  • Translation of the Neuroprotective Immune Modulator LBT-3627 into First-In-Human Studies


  • Pre-clinical Development of LBT-3627, a Potential Neuroprotective and Anti-inflammatory Therapy for Parkinson's Disease


  • Inflammatory Parkinson's Clinical Biomarker Profiling


  • VPAC2 Agonists Neuroprotective and Anti-inflammatory Effects in Parkinson's Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.